Lumida
/PRAX
⌘K
Praxis Precision Medicines Inc

Praxis Precision Medicines Inc

PRAX
$334.58USD-1.18%-3.99 today

MARKET CAP

9.3B

P/E (TTM)

FWD P/E

DAY RANGE

$334 – $348

52W RANGE

$37
$393

AI Summary

Stalk
Sell NowMedium

PRAX has broken multi-week support around $335 (Support Failure) and is trading below its 9/20 EMAs and the 50-day SMA, confirming bearish momentum. The primary Support Failure pattern signals sellers overwhelming buyers, with further downside likely toward the rising 200-day SMA near $311. Short-term momentum is negative, as price rejects resistance at declining EMAs. Medium-term bias remains bearish in Stage 3 distribution. While RSI is oversold, the structural context favors selling now into any rally under EMA resistance. The long-term uptrend above the 200-day SMA remains intact but is currently overshadowed by distribution dynamics.

  • $1.4B in cash and equivalents at Q1 2026 funds R&D and launch through 2028
  • NDA for ulexacultamide and relutrigine accepted; combined peak sales >$10B
  • Q1 2026 operating expenses surged 100% YoY to $106M, straining cash burn
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2023FY 2024TREND
Sales, Adj.$2.4M$8.6M
YoY %+249.5%
P / Sales56.3x161.1x
EV / Sales30.6x140.3x
Gross Profit, Adj.$2.4M$8.6M
YoY %+249.5%
Margin %100.0%100.0%
EV / Gross Profit30.6x140.3x
EBITDA, Adj.$-125.9M$-199.8M
YoY %+41.1%-58.7%
Margin %-5146.8%-2336.1%
EV / EBITDA-0.6x-6.0x
EBIT$-126.4M$-200.2M
YoY %+41.2%-58.4%
Margin %-5164.4%-2340.3%
EV / EBIT-0.6x-6.0x
Net Income$-123.3M$-182.8M
YoY %+42.4%-48.3%
Net Margin-5037.9%-2137.5%
EPS (GAAP)-$18.69-$10.21
YoY %+73.2%+45.4%